Scher R L, Ropka M E, Neal D A, Berr S, Trouard T, Deutsch B, Cantrell R W, Levine P A
Department of Otolaryngology, Head and Neck Surgery, University of Virginia Health Sciences Center, Charlottesville 22908.
Otolaryngol Head Neck Surg. 1990 Jan;102(1):34-40. doi: 10.1177/019459989010200106.
The use of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma as a serologic test for the detection of malignancy was first described in 1986. That report prompted the present study, which was undertaken to evaluate the efficacy of this test in differentiating patients who have head and neck malignancy from normal controls. Forty-six patients who had a biopsy-proven malignancy of the head and neck and 32 healthy individuals provided plasma for which the nuclear magnetic resonance spectrum was plotted, blind to patient diagnosis or group. The average line-width of methyl and methylene resonance was calculated. Significant differences (p less than 0.05) were found between the group with disease and the group with no disease for the methyl line-widths, using analysis of variance. In spite of this statistical difference, plotting of the values for the methyl, methylene, and average line-widths clearly demonstrated that these three oncolipid measures have no clinical use because of the tremendous overlap between the disease and nondisease groups. The findings of this study do not support the use of water-suppressed proton nuclear magnetic resonance spectroscopy as a clinically useful test for the diagnosis of head and neck malignancy.
1986年首次描述了使用血浆的水抑制质子核磁共振波谱作为检测恶性肿瘤的血清学检测方法。该报告促成了本研究，本研究旨在评估该检测方法在区分头颈部恶性肿瘤患者与正常对照方面的有效性。46名头颈部活检证实为恶性肿瘤的患者和32名健康个体提供了血浆，在对患者诊断或分组不知情的情况下绘制了核磁共振波谱。计算了甲基和亚甲基共振的平均线宽。使用方差分析发现，疾病组和无疾病组之间甲基线宽存在显著差异（p小于0.05）。尽管存在这种统计学差异，但甲基、亚甲基和平均线宽值的绘制清楚地表明，这三种肿瘤脂质测量方法没有临床用途，因为疾病组和非疾病组之间存在巨大重叠。本研究结果不支持使用水抑制质子核磁共振波谱作为诊断头颈部恶性肿瘤的临床有用检测方法。
